Author

Anna Robeva

Observed names: A Robeva, A S Robeva, A. Robeva, Anna S. ROBEVA, Anna S. Robeva, Robeva, A., Robeva, Anna

Observed institutions: Novartis (Switzerland), National Academy of Sciences of Ukraine, Emory University, University of Cologne, Universität Innsbruck, University of Zurich, University of Virginia Health System, University Hospital Heidelberg, ETH Zurich, Universitätsmedizin Göttingen, Novartis (United States), University of Virginia Medical Center, University Hospital Cologne, Novartis Institutes for BioMedical Research, École Polytechnique Fédérale de Lausanne, University of Virginia, University of Göttingen

OpenAlex ID: A5015460372

Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

2020 · Jürgen Wolf, Takashi Seto, et al. · New England Journal of Medicine · 1,003

PDF

Nogo-A Inhibits Neurite Outgrowth and Cell Spreading with Three Discrete Regions

2003 · Thomas Oertle, Marjan E. van der Haar, et al. · Journal of Neuroscience · 416

Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system

1998 · Diane L. Rosin, Anna Robeva, et al. · The Journal of Comparative Neurology · 389

Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.

1993 · J Linden, H E Taylor, et al. · Molecular Pharmacology · 204

Serum Amyloid A (apoSAA) Expression Is Up-Regulated in Rheumatoid Arthritis and Induces Transcription of Matrix Metalloproteinases

2001 · Rüdiger Vallon, Felix Freuler, et al. · The Journal of Immunology · 164

PDF

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

2007 · J B Singer, Y Shou, et al. · Leukemia · 123

Characterization of Human A2B Adenosine Receptors: Radioligand Binding, Western Blotting, and Coupling to Gq in Human Embryonic Kidney 293 Cells and HMC-1 Mast Cells

1999 · Joel Linden, Tami Thai, et al. · Molecular Pharmacology · 123

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

2019 · Juergen Wolf, Takashi Seto, et al. · Journal of Clinical Oncology · 111

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

2024 · Jürgen Wolf, Maximilian Hochmair, et al. · The Lancet Oncology · 86

A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition.

1994 · A L Tucker, A S Robeva, et al. · Journal of Biological Chemistry · 86

Molecular characterization of recombinant human adenosine receptors

1996 · Anna S. Robeva, Robin L. Woodard, et al. · Drug Development Research · 78

Double tagging recombinant A1- and A2A-adenosine receptors with hexahistidine and the FLAG epitope

1996 · Anna S. Robeva, Robin Woodard, et al. · Biochemical Pharmacology · 74

Cloning and expression of a bovine adenosine A1 receptor cDNA

1992 · Amy L. Tucker, Joel Linden, et al. · FEBS Letters · 56

PDF

Biochemistry and Pharmacology of Epitope-Tagged α1-Adrenergic Receptor Subtypes

2002 · Aleksandra Vicentic, Anna Robeva, et al. · Journal of Pharmacology and Experimental Therapeutics · 52

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

2018 · J. Wolf, T. Seto, et al. · Annals of Oncology · 40

PDF

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study

2014 · Michael Wang, Leslie L. Popplewell, et al. · British Journal of Haematology · 36

PDF

Purification of A1 adenosine receptor‒G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling

1999 · Zhenhai GAO, Anna S. ROBEVA, et al. · Biochemical Journal · 36

PDF

Synthetic and endogenous inhibitors of snake venom metalloproteinases.

1991 · A Robeva, V Politi, et al. · PubMed · 36

Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

2008 · Romain Séchaud, Anna Robeva, et al. · The Journal of Clinical Pharmacology · 26

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

2021 · Juergen Wolf, Edward B. Garon, et al. · Journal of Clinical Oncology · 25

Properties of recombinant adenosine receptors

1993 · Joel Linden, Amy L. Tucker, et al. · Drug Development Research · 22

Abstract CT082: Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)

2020 · Edward B. Garon, Rebecca S. Heist, et al. · Cancer Research · 20

Cmet-22. Capmatinib (inc280) in Metδex14-mutated Advanced Non-small Cell Lung Cancer (nsclc): Efficacy Data From the Phase 2 Geometry Mono-1 Study

2019 · Rebecca S Heist, Takashi Seto, et al. · Neuro-Oncology · 17

Signaling pathways activated by α1-adrenergic receptor subtypes in PC12 cells

2001 · Hongying Zhong, Deborah Lee, et al. · Life Sciences · 17

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

2010 · Owen A. O'Connor, Leslie Popplewell, et al. · Blood · 15

Works count: 51

Citation count: 3,336

H-index: 21

I10-index: 27